Teradyne, Inc. (TER) Stock Price Today
Aura AI Summary
Key Stats
- $60.84BMarket Cap
- 2,007,525Volume
- TechnologySector
- $483.8452W High
- $132.0552W Low
- 36 DaysTypical Hold Time
- $60.58BEnterprise Value
- 0.13%Div Yield
- 37% Sell | 63% BuyTrading Activity
Track Teradyne, Inc. (TER) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Teradyne, Inc. has traded between a low of $132.05 and a high of $483.84, highlighting its annual price range. Buy and sell Teradyne, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Most Recent News
General Mills sees 3% sales drop but beats earnings estimates with strong international growth.
General Mills reported a 3% decline in sales to $4.40 billion, partly due to selling its U.S. yogurt business, causing adjusted gross margin to fall to 33.3%. Despite this, the company beat earnings expectations with adjusted EPS of $0.75, helped by ...
BlackBerry's Q2 revenue jumps 26% with record QNX performance and raised full-year outlook
BlackBerry reported a 26% increase in Q2 revenue to $163.3 million, driven by a record quarter from its QNX automotive division. Adjusted EBITDA rose 81% to $47 million, and GAAP net income reached $33.9 million, marking six consecutive profitable qu...
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission.
Investors have filed a securities class action against Replimune Group, alleging the company misled the market by claiming its RP1 drug resubmission fully addressed FDA concerns, despite the FDA stating the trial data was inadequate. The lawsuit high...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.